710 Medtronic Parkway, NE
Medtronic, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Founders: Earl Bakken and Palmer Hermundlie
CEO: Omar Ishrak
CFO: Karen Parkhill
CSO (Scientific): Richard Kuntz
Please click here for Medtronic job opportunities.
Tweets by Medtronic
2247 articles with Medtronic
Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the world's largest medical technology, services, and solutions company — has been named on the 2021 list of Canada's Greenest Employers.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline™ Flex Embolization Device with Shield Technology™
IN.PACT™ AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Medtronic Canada ULC, a subsidiary of Medtronic plc — the world's largest medical technology, services, and solutions company — has been named on the 2021 lists of Top 50 Great Places to Work in Canada and Best Workplaces™ for Women for the second consecutive year after a thorough and independent analysis conducted by Great Place to Work®.
U.S. FDA Grants De Novo Clearance for First and Only Artificial Intelligence System for Colonoscopy; Medtronic Launches GI Genius™ Intelligent Endoscopy Module
- The GI Genius ™ Module Assists Physicians in Detecting Pre-Cancerous Growths; Potentially Addressing 19 Million Colonoscopies Annually - Transformative AI Colorectal Cancer Prevention Platform Expands Medtronic Capabilities in Medical Technology Data Analytics and Insights
Medtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with Diabetes
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes.
The Medtronic Foundation and Children's Heartlink Focus New Partnership on Health Equity for 10,000 Children and 10,000 Health Workers in Underserved Countries
The $2.5 Million USD Multi-Year Partnership Builds Capacity to Provide Pediatric Heart Surgery to 10,000 Children and Trains 10,000 Health Workers in Brazil, India, and China.
Medtronic Receives FDA Approval for Breakthrough Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease
Harmony™ Transcatheter Pulmonary Valve is First Minimally Invasive Alternative for Patients with Severe Pulmonary Regurgitation Who Have a Native or Surgically-Repaired Right Ventricular Outflow Tract
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the CE (Conformité Européenne) Mark for the SenSight™ directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms
The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021 , approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2020.
Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
Medtronic plc, the global leader in medical technology, announced the first procedures in the investigational device exemption pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation.
- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94 ; Q3 Non-GAAP Diluted EPS of $1.29
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of its InterStim™ II and InterStim™ Micro sacral neuromodulation (SNM) systems that use SureScan™ MRI leads.
Medtronic plc, the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences, with its executives answering questions about the company:
Surgeons Complete First Procedures Across the U.S. Utilizing Medtronic's Midas Rex™ Drills and Navigated Disc Prep and Interbodies with the Mazor™ Robotic Guidance System
Dr. Gregory Poulter of OrthoIndy , Dr. Sharad Rajpal of Boulder Neurosurgical & Spine Associates and Dr. Eiman Shafa of Twin Cities Spine Center Are First in the U.S. to Complete Surgeries Using the Most Comprehensive Integrated Spine Surgery Platform Available
Medtronic plc (NYSE:MDT) announced today that it will report financial results for its third quarter of fiscal year 2021 on Tuesday, February 23, 2021 . A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://newsroom.medtronic.com .
New Study in Newborns Finds Nellcor™ Pulse Oximetry Technology Provides Faster Stable Oxygen Saturation Readings Than Masimo Pulse Oximeter
Nellcor™ Pulse Oximetry Technology Demonstrated Statistically Significant Difference in Time to Deliver a Stable Oxygen Saturation Value and Heart Rate
Medtronic Announces Early Site Release of New Radial Artery Access Portfolio Following First-in-Patient Procedure
Acquisition of RIST Neurovascular Enhances Medtronic's Capabilities to Serve Patients Treated for Brain Aneurysms and Other Neurovascular Conditions